Repligen posts 13% organic growth, eyes stronger 2027 with BioLife acquisition boosting margins

Repligen reported 13% organic growth despite challenges in its Filtration segment, which is expected to recover with mid-single-digit growth by 2026. The company’s Proteins and Process Analytics segments are showing strong momentum. The recent acquisition of BioLife adds high-margin, recurring cell therapy consumables, promising synergies and increased earnings per share after closing. Although Repligen currently trades at a premium valuation, expected margin expansion and backlog growth could drive significant upside if execution remains solid.

Repligen's stock is currently trading at USD 178.86 on Pluang, showing a 1.96% increase in the last day. As of Oct 15, 2026 11:11 WIB, the stock maintains a market cap of $11.14 billion with strong buy interest from Pluang users.